Skip to main content

Arch Biopartners Inc(ARCH-X)
TSX Venture

Today's Change
Delayed Last Update

Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

Globe Newswire - Fri Aug 5, 2022

TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with novel therapeutics, announced today that the Company has added Dr. David Luke as a Strategic Advisor for the clinical trial development of the Company’s drug candidates.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe